Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations.

Authors : Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, Cortes J, Piccart-Gebhart M, Wolff AC, Viale G, Gelber Rd
Year : 2022
Journal : JAMA Oncol
Volume : 8
Pages : 1668-1675

Systemic therapy for early-stage breast cancer: learning from the past to build the future.

Authors : Agostinetto E, Gligorov J, Piccart-Gebhart M
Year : 2022
Journal : Nat Rev Clin Oncol
Volume : 19
Pages : 763-774

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit.

Authors : Oosting SF, Barriuso J, Bottomley A, Galotti M, Gyawali B, Kiesewetter B, Latino NJ, Martinelli F, Pe M, Pentheroudakis G, Roitberg F, Vachon H, de Vries EGE, Piccart-Gebhart M, Cherny NI
Year : 2022
Journal : Ann Oncol

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.

Authors : Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, OShaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 72

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.

Authors : Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 87

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.

Authors : Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E
Year : 2022
Journal : J Cancer Res Clin Oncol
Pages : 1-6

ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.

Authors : Agostinetto E, Nader-Marta G, Paesmans M, Ameye L, Veys I, Buisseret L, Neven P, Taylor D, Fontaine C, Duhoux FP, Canon JL, Denys H, Coussy F, Chakiba C, Ribeiro JM, Piccart M, Desmedt C, Ignatiadis M, Aftimos P
Year : 2022
Journal : Future Oncol
Volume : 18
Pages : 2383-2392

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Authors : Piccart-Gebhart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber Rd, Viale G, Thomssen C
Year : 2021
Journal : J Clin Oncol
Volume : 39
Pages : 1448-1457

Flexible care in breast cancer.

Authors : Wardley A, Canon JL, Elsten L, Peña Murillo C, Badovinac Crnjevic T, Fredriksson J, Piccart-Gebhart M
Year : 2021
Journal : ESMO Open
Volume : 6
Pages : 100007

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.

Authors : Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart-Gebhart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI
Year : 2021
Journal : ESMO Open
Volume : 6
Pages : 100117

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Authors : Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, OShaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS
Year : 2021
Journal : N Engl J Med
Volume : 384
Pages : 1529-1541

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.

Authors : Bines J, Clark E, Barton C, Restuccia E, Procter M, Sonnenblick A, Fumagalli D, Parlier D, Arahmani A, Baselga J, Viale G, Reaby LL, Frank E, Gelber Rd, Piccart-Gebhart M, Jackisch C, Petersen JA
Year : 2021
Journal : Br J Cancer
Volume : 125
Pages : 38-47

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

Authors : Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber Rd, Piccart-Gebhart M
Year : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 287-296

Overcoming Barriers to Clinical Trials Cooperation: The Breast International Group Example.

Authors : Piccart-Gebhart M, Goulioti T, Straehle C, Cameron D
Year : 2021
Journal : Am Soc Clin Oncol Educ Book
Volume : 41
Pages : 1-9

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

Authors : Piccart-Gebhart M, van t Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT
Year : 2021
Journal : Lancet Oncol
Volume : 22
Pages : 476-488

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Authors : Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada A, Santoro A, Piccart-Gebhart M, de Azambuja E
Year : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 76-91

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.

Authors : Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M, de Azambuja E
Year : 2021
Journal : Eur J Clin Invest
Pages : e13535

Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis.

Authors : Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart-Gebhart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S
Year : 2021
Journal : Clin Cancer Res

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 125

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.

Authors : Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart-Gebhart M, Cowden J, Spears P, Carey LA
Year : 2021
Journal : Future Oncol